AB
BIO icon

Amalgamated Bank’s Bio-Rad Laboratories Class A BIO Stock Holding History

Amalgamated Bank’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.34M Sell
7,979
-217
-3% -$61.5K 0.02% 756
2026
Q1 		$2.29M Buy
8,196
+208
+3% +$59.9K 0.02% 746
2025
Q4 		$2.42M Sell
7,988
-368
-4% -$115K 0.02% 731
2025
Q3 		$2.34M Sell
8,356
-163
-2% -$44.4K 0.02% 740
2025
Q2 		$2.06M Sell
8,519
-413
-5% -$97.6K 0.02% 781
2025
Q1 		$2.17M Sell
8,932
-282
-3% -$84.8K 0.02% 730
2024
Q4 		$3.03M Buy
9,214
+181
+2% +$61.4K 0.02% 622
2024
Q3 		$3.02M Buy
9,033
+4,921
+120% +$1.56M 0.02% 640
2024
Q2 		$1.12M Sell
4,112
-262
-6% -$76.2K 0.01% 1008
2024
Q1 		$1.51M Sell
4,374
-671
-13% -$221K 0.01% 938
2023
Q4 		$1.63M Sell
5,045
-240
-5% -$75.2K 0.01% 985
2023
Q3 		$1.89M Sell
5,285
-370
-7% -$143K 0.02% 887
2023
Q2 		$2.14M Sell
5,655
-48
-0.8% -$19.5K 0.02% 849
2023
Q1 		$2.73M Sell
5,703
-2,185
-28% -$1.02M 0.02% 745
2022
Q4 		$3.32M Buy
7,888
+2,438
+45% +$984K 0.03% 697
2022
Q3 		$2.27M Sell
5,450
-288
-5% -$144K 0.02% 781
2022
Q2 		$2.84M Sell
5,738
-36
-0.6% -$18.7K 0.03% 720
2022
Q1 		$3.25M Sell
5,774
-371
-6% -$224K 0.03% 712
2021
Q4 		$4.64M Buy
6,145
+66
+1% +$49.4K 0.03% 557
2021
Q3 		$4.54M Sell
6,079
-217
-3% -$163K 0.04% 557
2021
Q2 		$4.06M Buy
6,296
+5,137
+443% +$3.13M 0.03% 649
2021
Q1 		$662K Sell
1,159
-43
-4% -$25.5K 0.02% 819
2020
Q4 		$701K Sell
1,202
-2
-0.2% -$1.14K 0.03% 767
2020
Q3 		$621K Sell
1,204
-21
-2% -$10.6K 0.03% 721
2020
Q2 		$553K Sell
1,225
-3,571
-74% -$1.58M 0.03% 777
2020
Q1 		$1.68M Sell
4,796
-96
-2% -$35.3K 0.04% 422
2019
Q4 		$1.81M Buy
4,892
+510
+12% +$180K 0.03% 552
2019
Q3 		$1.46M Sell
4,382
-63
-1% -$20.6K 0.03% 588
2019
Q2 		$1.39M Buy
4,445
+211
+5% +$63.2K 0.03% 611
2019
Q1 		$1.29M Buy
4,234
+72
+2% +$19.4K 0.03% 602
2018
Q4 		$966K Sell
4,162
-56
-1% -$15K 0.03% 663
2018
Q3 		$1.32M Sell
4,218
-6
-0.1% -$1.86K 0.03% 543
2018
Q2 		$1.22M Buy
4,224
+31
+0.7% +$8.56K 0.03% 658
2018
Q1 		$1.05M Sell
4,193
-34
-0.8% -$8.66K 0.03% 682
2017
Q4 		$1.01M Buy
4,227
+238
+6% +$57.7K 0.03% 706
2017
Q3 		$886K Sell
3,989
-118
-3% -$26.6K 0.03% 714
2017
Q2 		$929K Buy
4,107
+819
+25% +$178K 0.03% 696
2017
Q1 		$655K Buy
3,288
+96
+3% +$18.5K 0.03% 679
2016
Q4 		$582K Buy
3,192
+370
+13% +$63.1K 0.03% 757
2016
Q3 		$462K Buy
2,822
+1
+0% +$152 0.03% 780
2016
Q2 		$436K Buy
2,821
+322
+13% +$45.9K 0.03% 804
2016
Q1 		$342K Buy
2,499
+214
+9% +$28.1K 0.03% 796
2015
Q4 		$317K Sell
2,285
-151
-6% -$20.9K 0.04% 737
2015
Q3 		$327K Buy
2,436
+26
+1% +$3.74K 0.03% 819
2015
Q2 		$363K Buy
+2,410
New +$345K 0.04% 814

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Amalgamated Bank's BIO Position: Q2 2026 in Review

Amalgamated Bank reduced its Bio-Rad Laboratories Class A (BIO) stake by 2.6% in Q2 2026, selling an estimated $61.5K and leaving 7,979 shares worth $2.34M. The position accounts for 0.02% of the portfolio, ranked #756.

Amalgamated Bank first reported a position in BIO in Q2 2015 and has held it in 45 quarters since. The position peaked at $4.64M in Q4 2021. 185 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Amalgamated Bank held 7,979 shares of Bio-Rad Laboratories Class A worth $2.34M as of Q2 2026.
  • Amalgamated Bank sold 217 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $61.5K.
  • Bio-Rad Laboratories Class A made up 0.02% of Amalgamated Bank's portfolio in Q2 2026, its #756 holding.
  • Amalgamated Bank first reported a position in Bio-Rad Laboratories Class A in Q2 2015 and has held it in 45 quarters since.
  • Amalgamated Bank's Bio-Rad Laboratories Class A position peaked at $4.64M in Q4 2021.
  • 185 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Amalgamated Bank's 13F filing for Q2 2026, filed 23 Jul 2026.